The Fight Against Malaria Is Stalling: What's Holding Us Back?
- Apr 25
- 3 min read
Malaria is often discussed in statistics - case numbers, death rates, progress toward elimination. But behind those numbers are lived experiences that tell a more urgent story.
“It’s a feeling that you didn’t want to experience… it is something that you wouldn’t want to experience.”
For Nyasha Nguluwe, a Medical Laboratory Scientist visiting ZiP from Malawi, Malaria is not abstract. It is personal.
“I’ve actually suffered from malaria almost three times. I would say I’m a survivor… it’s a very bad disease.”
His experience reflects the reality for millions of people living in endemic regions, where malaria remains persistent, and in many cases, deadly.
“The cases are still high… and it’s still fatal.”
What is Malaria?
Malaria is caused by parasites of the Plasmodium genus - including species such as Plasmodium falciparum and Plasmodium vivax - each behaving slightly differently in how they infect and persist in the body.
What makes malaria particularly challenging is its unique lifecycle.
“It’s a eukaryotic organism… a parasite that has both the sexual stage that occurs in the mosquito and the asexual stage that occurs in people.”
This dual lifecycle creates a cycle of transmission that is difficult to break. Even when a patient is treated and symptoms improve, transmission remains a persistent risk.
“You can heal a person… but they will still carry a transmissible stage… able to be passed on to someone else.”
According to Dr Hayley Buchanan, this is one of the reasons Malaria continues to circulate, and often silently.
“The burden of asymptomatic infections for malaria is huge.”
Progress Has Been Made, But It’s Not Evenly Distributed
There have been important advances in malaria control, including the rollout of vaccines such as RTS,S and R21. But challenges remain.
“They’re not hugely effective and they’re very, very difficult to be able to distribute.”
Access plays a defining role in outcomes.
“In areas that can afford to put a few more things in place… it’s a lot easier to control that sort of disease.”
In many parts of the world, geography alone can determine survival.
“The distance to arrive at the hospital is quite huge. So someone can die of malaria from the villages without even reaching the hospital.”
The Diagnostic Gap
One of the most consistent themes across both lived and clinical perspectives is the challenge of diagnosis.
In ideal settings, malaria is confirmed using microscopy - the gold standard.
“The gold standard diagnostic method is microscopy which requires a highly trained technician and laboratory environment.”
But in many settings, that level of infrastructure isn’t available.
Rapid tests are more accessible - but they come with limitations.
“They end up missing some cases… we were finding them positive on the microscope.”
“Lateral flow tests can miss certain infections… sometimes [the target protein] is not expressed.”
This creates a difficult trade-off:
High sensitivity → lab-based, less accessible
High accessibility → faster, but less sensitive
“It’s always about getting the right balance between sensitivity and accessibility.”
Why Early Diagnosis Changes Outcomes
Despite the complexity, one thing is clear: timing matters.
“Early and rapid diagnosis… allows timely treatment, it prevents complications and also reduces the chance of onward transmission.”
Accurate diagnosis also ensures the right treatment is given.
“You want to pinpoint the disease you’re treating… so you can choose the appropriate drug.”
When diagnosis is delayed or missed, the consequences extend beyond the individual — affecting entire communities.
Bridging the Gap
The challenge now is not just scientific, it’s practical.
How do we deliver high-quality diagnostics in the places that need them most?
“If we can have a rapid test that can be used right in those little areas… with high sensitivity… a lot of people can be getting treatment first.”
This is where new approaches, including molecular diagnostics, are changing what’s possible. The goal is clear: to close the gap between what’s technically possible and what’s practically accessible.
it's always about getting the right balance between sensitivity and accessibility.
"It's always about getting the right balance between sensitivity and accessibility. For example, lab-based testing is highly sensitive, but it's not always practical in the field. On the other hand, you have in-field testing, which are usually much more accessible and easier to use, but it can miss certain low-level infections. And I guess bridging that gap is exactly what we are trying to work on here at ZiP.
Why This Matters
Malaria is not just a disease of biology, it’s shaped by access, infrastructure, and timing. And while progress continues, outcomes are still heavily influenced by how quickly a case is identified.
That’s why the focus on point-of-care diagnostics remains so important - not as a standalone solution, but as a critical piece of the system that enables faster decisions, earlier treatment, and more effective control.
Because in Malaria, time doesn’t just matter, it defines the outcome.
